Faculty Opinions recommendation of Mesenteric tumor deposits in midgut small intestinal neuroendocrine tumors are a stronger indicator than lymph node metastasis for liver metastasis and poor prognosis.

Author(s):  
Noam Harpaz ◽  
Alexandros Polydorides
BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Bo Zhou ◽  
Jie Xiang ◽  
Ming Jin ◽  
Xiang Zheng ◽  
Guogang Li ◽  
...  

Abstract Background Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of neoplasms with malignant behaviors that can develop from inert slow growth or low malignancy to aggressive metastasis during follow-up. Recently, vimentin and E-cadherin were shown to be prognostic markers in some malignant tumors but were not evaluated in pNETs. The aim of this study was to evaluate the expression and prognostic significance of vimentin and E-cadherin in grade 1 and 2 pNETs. Methods A retrospective review of 227 patients with grade 1 and 2 pNETs undergoing surgical resection was conducted. Tumor specimens were immunohistochemically stained for vimentin and E-cadherin. Correlations between vimentin and E-cadherin expression and other clinicopathological features were then analyzed. Furthermore, overall survival (OS) and disease-free survival (DFS) were evaluated using Kaplan-Meier and univariate and multivariate Cox regression methods. Results Among 227 patients, 55 (24.2%) harbored tumors with high vimentin expression, while 117 (51.5%) harbored tumors with loss of E-cadherin expression. Patients with high vimentin expression and loss of E-cadherin expression had significantly elevated risks of lymph node metastasis, distant metastasis, perineural invasion and an advanced American Joint Committee on Cancer (AJCC) stage compared with those with low vimentin expression and preserved E-cadherin expression, high vimentin expression and preserved E-cadherin expression, or low vimentin expression and loss of E-cadherin expression. Furthermore, multivariate analysis showed that high vimentin expression with loss of E-cadherin expression was an independent predictor of OS and DFS in patients with grade 1 and 2 pNETs who underwent resection (both P < 0.001). Conclusions The current study demonstrated that high vimentin expression with loss of E-cadherin expression was correlated with lymph node metastasis, distant metastasis, disease progression and a poor prognosis in patients with grade 1 and 2 pNETs who underwent resection.


PLoS ONE ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. e0211675 ◽  
Author(s):  
Hajime Ushigome ◽  
Yosuke Fukunaga ◽  
Toshiya Nagasaki ◽  
Takashi Akiyoshi ◽  
Tsuyoshi Konishi ◽  
...  

2021 ◽  
pp. 538-544
Author(s):  
Nozomi Karakuchi ◽  
Senichiro Yanagawa ◽  
Kei Kushitani ◽  
Shinya Kodama ◽  
Yukio Takeshima ◽  
...  

Sarcomatoid carcinoma (SC) is a rare malignant tumor with properties of both epithelial and mesenchymal carcinomas. SC has been reported in various organs, but the number of reports for each type is small. Small intestinal tumors make up about 3–6% of gastrointestinal malignancies. Discovering them in the early stage is rare and difficult, with anemia and/or abdominal pain as the major symptoms of small intestinal tumors. Primary small intestinal SC (SISC) is rare among small intestinal tumors, and currently very few cases have been reported in the literature. Previous studies have reported that neither chemotherapy nor radiotherapy improves the overall survival rate of patients with SISC, and the prognosis is extremely poor. Currently, surgical resection remains the only optimal therapeutic approach for SISC. Here, we present the case of a 90-year-old woman who had acute peritonitis due to perforation of a small intestinal tumor. She underwent emergency exploratory laparotomy and partial resection of the small intestine, including the tumor. The tumor was pathologically identified as a primary SISC with mesenteric lymph node metastasis. Subsequently, she had recurrence in the intra-abdominal area and lymph node metastasis anterior to the inferior vena cava and died 15 months after surgery without any additional treatment.


Medicine ◽  
2020 ◽  
Vol 99 (21) ◽  
pp. e20238
Author(s):  
Zeying Guo ◽  
Ziru Yang ◽  
Dan Li ◽  
Jinlong Tang ◽  
Jinghong Xu ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Yuqing Cheng ◽  
Mingzhan Du ◽  
Xiaoli Zhou ◽  
Lingchuan Guo ◽  
Kequn Xu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document